Home - Clinical Proteomic Technologies for Cancer

Click on a program below


Technology Assessment / Optimization	Advanced Platforms and Computational Sciences	Proteomic Reagents and Resources Core

Summary:

The Clinical Proteomic Technologies for Cancer initiative is a five-year, $104 million initiative to build the foundation of technologies, data, reagents and reference materials, analysis systems, and infrastructure needed to systematically advance protein biology for the diagnosis, treatment and prevention of cancer.

CPTC Milestones Timeline

2007 Annual Report

Technology Assessment/Optimization:

Clinical Proteomic Technology Assessment for Cancer is a multidisciplinary network of teams conducting rigorous technology assessment; developing standard protocols and clinical reference sets; and evaluating methods to ensure data reproducibility.

Advanced Platforms and Computational Sciences:

Advanced Proteomic Platforms, Analytical Methods, and Computational Sciences supports the development of innovative new tools, reagents, and enabling technologies for protein/peptide measurement; supports algorithm development and computational methods to interrogate emerging pre-processed data sets.

Proteomic Reagents and Resources Core:

The Proteomic Reagents and Resource Core is being developed for the entire cancer proteomic community as a central repository of the tools, reagents, enabling technologies, and other critical resources to support protein/peptide measurement and analysis efforts.

Mouse Initiative:

The Mouse Proteomic Technologies Initiative is a multidisciplinary and collaborative team effort to use animal models to develop and standardize technologies that help improve the accurate measurement of proteins and peptides relevant to cancer.